{"name":"Avidity Biosciences, Inc.","slug":"avidity-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AOC 1001 (del-desiran)","genericName":"AOC 1001 (del-desiran)","slug":"aoc-1001-del-desiran","indication":"Desmin-related myopathy (DRM)","status":"phase_3"},{"name":"AOC 1001","genericName":"AOC 1001","slug":"aoc-1001","indication":"Other","status":"phase_2"},{"name":"AOC 1044","genericName":"AOC 1044","slug":"aoc-1044","indication":"Treatment of myasthenia gravis","status":"phase_2"},{"name":"AOC-1020","genericName":"AOC-1020","slug":"aoc-1020","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Del-desiran (AOC 1001)","genericName":"Del-desiran (AOC 1001)","slug":"del-desiran-aoc-1001","indication":"Hypertriglyceridemia","status":"phase_3"}]}],"pipeline":[{"name":"AOC 1001 (del-desiran)","genericName":"AOC 1001 (del-desiran)","slug":"aoc-1001-del-desiran","phase":"phase_3","mechanism":"AOC 1001 is an antisense oligonucleotide conjugate that targets and reduces expression of a disease-causing gene through a tissue-directed delivery approach.","indications":["Desmin-related myopathy (DRM)"],"catalyst":""},{"name":"AOC 1001","genericName":"AOC 1001","slug":"aoc-1001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AOC 1044","genericName":"AOC 1044","slug":"aoc-1044","phase":"phase_2","mechanism":"AOC 1044 is an investigational antisense oligonucleotide.","indications":["Treatment of myasthenia gravis"],"catalyst":""},{"name":"AOC-1020","genericName":"AOC-1020","slug":"aoc-1020","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Del-desiran (AOC 1001)","genericName":"Del-desiran (AOC 1001)","slug":"del-desiran-aoc-1001","phase":"phase_3","mechanism":"Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.","indications":["Hypertriglyceridemia","Cardiovascular risk reduction in patients with elevated triglycerides"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQX3Nkc0FTNk5HNHNFUlYtYktjeEpqaGdrdFBpR2hDckx2RlQySWJBXzk3bGRCS2dQejFBbGtBNFdGaVZPS20xQy00MFF2MzktUkRQaDBUNlY2ZmxjNm9QbDMxaXAwRVg4Y1NVbWhxMmxCUEJhWC1WOFVMdTFNQzJZRmlQR3FUTzZ1WFJGektlNFdoQnRmOTZCbGh2Y2tBMFFaa1I0MzdWOHNKc0M3RW1uMGR0WTEzZWQ2TUxVVkJKTWM?oc=5","date":"2026-02-27","type":"deal","source":"Fierce Biotech","summary":"Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech","headline":"Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOdno1eHVIYmFiLUhHODloZ1dxd3BKMzlGczlfTkludXE2dTZpWXZ0TWI0N213aDg3RkVGOFliRnlDa0xleUY5VXR2WHltQkxpZVhQSnl0YzZyTE85eDRMRXk1ZV9MVkpTR1VTbHRKZVdBcUV4UER1YW1mR2tEY1VYMEdwMVpPMHZuX09rSHpLX29rWi1Q?oc=5","date":"2026-02-02","type":"pipeline","source":"Investing News Network","summary":"Avidity Biosciences Announces Expected Record Date for Spin-Off - Investing News Network","headline":"Avidity Biosciences Announces Expected Record Date for Spin-Off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZDJ5aGE2bkYwT3Z2X1liY1dzcllMeGNUX0VIU2xJN0M4WTYtYnpEb1h5Q2JwLTYwU09LYnlQUm1rZnp6OHBsX0hNTVYwcHVFNlVFUGswVzZJXzJGUEZqSVIxS1ctenlrS2ZuZkZYSEg0eW1YU0N0TW5adnpvejJfLXZ5Vm9NTTJ0bE5nSVpHRWdCRUp3U2x0VlVROWRwaVB1Vjgw?oc=5","date":"2025-10-28","type":"deal","source":"Pharma Voice","summary":"Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience - Pharma Voice","headline":"Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVHdwZjZBdkpiT18wdlh4V3FHTEcxVmp4OGJ3cmZfLVhoa015ZjJwTEpEZC1fb09JLTlPVUlBR0ZoVFFWanVmLTNNdVJCR29qUUdEeVFaUlVNS3ZkZEtmeURlZF9FTG5JQkVhLTMzdXRNN0ZYeHFrYllyQkdUa1dNT0pwbFlDRGdmVnNlUjctUVNIV1dGTTdfb1FTWWhweTJiRElJdF9pajJEVDhySEgzZEZXVDlqVVlJTWhN?oc=5","date":"2025-10-27","type":"deal","source":"Reuters","summary":"Novartis to acquire Avidity Biosciences for about $12 billion - Reuters","headline":"Novartis to acquire Avidity Biosciences for about $12 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNdTNaeU9MNDdoSmRsUHNDaGtyRXM2V3lSSzJuc29ERm1EZ05LOWhkMDB4OExjWU5oVTV4RGFONWN3RUZTWGVzaVg1Tm40VGd6dGlpZnM4alAxUHY4RVdpanEwaVlfWlB2VFE0a1Y5SEVGSWFmZGNkSGM2VGJQbE82VmRwWjdoZ1dFQ1RiLVliTUhmdkFvWTd3?oc=5","date":"2025-10-27","type":"deal","source":"Contract Pharma","summary":"Novartis Agrees to Acquire Avidity Biosciences - Contract Pharma","headline":"Novartis Agrees to Acquire Avidity Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQTVdHZ1pBcUFkMkRvelNyRlVNdWo1djJCcjk4RGZKRzJpNGhnOFhwTmktMHlxTTFxc2NfRG9DNy1EUXVSY2xWY3BGUC1Sdm4zbTc1TnN1LUFwUkdCM0ZlNUctU0c5RnNZWlBNem4zYlhCaTM3UlktQXFwZ0dzVnBPX0xRd1ViUQ?oc=5","date":"2025-10-27","type":"deal","source":"Pharmaceutical Technology","summary":"Novartis signs agreement to buy Avidity Biosciences for $12bn - Pharmaceutical Technology","headline":"Novartis signs agreement to buy Avidity Biosciences for $12bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZW1PcUdQVENlVjNCczB1UC0xLVFlNUhvQnFENzkycDFORzc4TkFMc0J6NWxMdUtZMzdkc0JqZ1p0OGhqSW03WU9kMkRPR2sySjVNaG9ESU10RFo0eExua3pLbzY2LTVMb1FjeFU4Mi1zZURnNEF1UzkxMFN2TXJQMXZvYTJEZVpGdlJabmwyN2pLV1ZGYkdTWm4wV2FDNkttdXF6ZkNuX3h5RDRaVUxVaUJuZ1lheXpz?oc=5","date":"2025-10-27","type":"pipeline","source":"MedCity News","summary":"Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition - MedCity News","headline":"Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNcVRJQkpLMll1QnNSZDY2ZWZvTU9ZUC1TUUFzeDR4NjJCMmtLOTY1RkFseWtwZTNNLWVwX1FUci1lWUt5XzVIV1N6N3F1V1owbjFPWFlyYk50WUkyQlJ3VjQwRkNDNERGLTQwNmpJMEk2SC1ScXliMU5vV2d0bURnbFZCb0EwTE1QZmFrbTN4dE82M0VFVU9FN1B0bWJOalhtbkVxUXR2b0phMDJmRTliWVNDQkhhdlBYQWRWYXVpSzVWeUho?oc=5","date":"2025-10-27","type":"regulatory","source":"Barron's","summary":"S&P 500 Futures Climb in Premarket Trading; Avidity Biosciences, BridgeBio Pharma Lead - Barron's","headline":"S&P 500 Futures Climb in Premarket Trading; Avidity Biosciences, BridgeBio Pharma Lead - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQeGRJdXhaSXlmVzFVMUpDNzIyem05enFLUUxzUWlPazNnM3JCVHhHUk9vZGxhU2FkZlFDX3hjbXRZcnQtSm96cjI3SVloLUNPbzB1cFVwRzhvZWEwNlluMDBnY3NTMnQwT3ptZUpnWHJrbVdOR3c4UnpqZkJucHNHZHE5OA?oc=5","date":"2025-10-27","type":"deal","source":"pharmaphorum","summary":"Novartis makes $12bn wager on RNA drugs with Avidity buy - pharmaphorum","headline":"Novartis makes $12bn wager on RNA drugs with Avidity buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPcXhHOHgxcFVQaHltdXJkSGU2VDh4eVNja29IZmZrMVl1LS00Vi1OZXY3VENmSXFGcV9lSjVQdndZbDJDel9EbEwtWTNBRkU3YjkwR05vb0dtZ3Fsdm9OUENFcFo1RDdBZXdUMXBST3dCNXJtS0E1ZFlhbUdScGU3cEFmbHYzX0FNVFBjNkE1Q3h4UQ?oc=5","date":"2025-10-26","type":"deal","source":"statnews.com","summary":"Novartis to buy RNA-focused Avidity in $12 billion deal - statnews.com","headline":"Novartis to buy RNA-focused Avidity in $12 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNeG9fekIzQWdlMWtwY1dTRkxfMFVCRmYwdUJlanpmU0hEM0o5a2xXV1p0NjlnV2s4VUZnVncyOUk2alVfR3BOVUtKb3F1U2hjUEg0OFZ0R0FPSlJQRmNya3pxYjdnWk9VMFpOMWFETDZBNzU1UTJwRk10ZHpqOEdIYjRzQXFOM1BZQTc1bWZUdWpVeVV6cVNjRVpKMWViTEc2dzNYY1g3MA?oc=5","date":"2025-10-26","type":"deal","source":"BioPharma Dive","summary":"Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease - BioPharma Dive","headline":"Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQX0FwZUFLdlI4aXh3YzlkVXQ1ZU9RTTFPVjJkRkdfeWZBSGh0SGxiVzMyS3ByRThQelRVLTBaUUZ2dVd3MS0tWmtmYVVkVGxkWHZfOWVjY0pDSmliQjN2cllBNlhfU2hiRkJ2SHBJLWZIazloOUtfdEQ1UlJKT0dObDdnYUpyNjVobDVRNTZiXzN1ZFZWblozUElpaU9rSHZoY09oS253?oc=5","date":"2025-10-26","type":"deal","source":"wsj.com","summary":"Novartis Agrees to Acquire Avidity Biosciences for $12 Billion - wsj.com","headline":"Novartis Agrees to Acquire Avidity Biosciences for $12 Billion","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}